Contrast agent developer Nycomed of Oslo, Norway, has received a second approvable letter from the Food and Drug Administration for its Teslascan (mangafodipir trisodium) liver imaging agent for MRI studies. Teslascan had received an approvable letter
Contrast agent developer Nycomed of Oslo, Norway, has received a second approvable letter from the Food and Drug Administration for its Teslascan (mangafodipir trisodium) liver imaging agent for MRI studies. Teslascan had received an approvable letter last September, but the FDA raised additional questions about the agent's application that the company has been working to resolve (SCAN 10/9/96). With the second approvable letter now in hand, Nycomed expects final approval shortly, according to a spokesperson for the company's U.S. subsidiary in Princeton, NJ.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.